Niedermolekulare Heparine in der Kardiologie

W. Lankes; D. C. Gulba

doi:10.1055/s-0037-1619511

Hämostaseologie, Table of Contents

Hamostaseologie 2001; 21(03): 125-129
DOI: 10.1055/s-0037-1619511

Original article

Schattauer GmbH

Niedermolekulare Heparine in der Kardiologie

In der Therapie der instabilen Angina pectoris heute schon »state-of-the-art«^[*] Low-molecular-weight heparins in cardiology

Authors

W. Lankes

¹Charité – Humboldt-Universität zu Berlin, Franz-Volhard-Klinik
D. C. Gulba

²Krankenhaus Düren gGmbH, Medizinische Klinik I mit Schwerpunkt Kardiologie, Angiologie und Pulmonologie

Abstract

Zusammenfassung

Bei thromboembolischen Herzerkrankungen hat sich unfraktioniertes Heparin in hohen Dosen als außerordentlich wirksam erwiesen. Bei der subkutanen Verabreichung muss jedoch mit einer unsicheren Resorption aus dem subkutanen Fettgewebe gerechnet werden, weshalb im Allgemeinen eine intravenöse Heparin-Dauerinfusion bevorzugt wird. Das ungünstige pharmakologische Profil der Substanz und die hohen inter- und intraindividuellen Schwankungen der Dosis-Wirkungs-Beziehung ziehen jedoch bei intravenöser Verabreichung die Notwendigkeit engmaschiger Laborkontrollen nach sich (Übersicht bei [1, 2]).

Die Frühmobilisation und die Erhaltung der Mobilität kardial erkrankter Patienten nehmen heute in der Therapie einen dominanten Platz ein. Die Notwendigkeit der intravenösen Verabreichung ebenso wie die Komplexität der Therapie stehen bei den unfraktionierten Heparinen der Frühmobilisation und der ambulanten Fortführung der Behandlung entscheidend entgegen. Mit den fraktionierten (niedermolekularen) Heparinen steht nunmehr eine Heparinklasse zur Verfügung, die neben der verlässlichen Resorption aus dem subkutanen Fettgewebe auch eine wesentlich besser vorhersagbare Dosis-Wirkungs-Beziehung aufweist (Übersicht bei [1, 2]). Da diese Heparine darüber hinaus bei der primären Anwendung sehr viel seltener mit der Ausbildung einer lebensgefährlichen HIT (Heparin-induzierte Thrombozytopenie) assoziiert sind (3), wird ihr routinemäßiger Einsatz auch bei kardiologisch erkrankten Patienten immer häufiger erwogen. Das instabile Koronarsyndrom (instabile Angina pectoris und nicht-transmuraler Herzinfarkt) nimmt diesbezüglich eine Vorreiterrolle in der Kardiologie ein.

Summary

Full-dose unfractionated heparin has proved to be extraordinarily effective in thromboembolic heart diseases. However, unreliable absorption in the subcutaneous fatty tissue after subcutaneous administration must be expected, so continuous intravenous infusions are generally preferred. Nevertheless, the unfavourable pharmacological profile of the substance, and the broad inter- and intraindividual fluctuations of the dose/effect relationship following intravenous administration require close biochemical monitoring (Summary see [1, 2]). Early ambulation and retaining mobility for heart patients play a dominant role in current therapy. The need for intravenous administration and the complexity of therapy are convincing opposing factors against early mobilisation and continuing outpatient treatment with unfractionated heparin. The fractionated (low molecular weight) heparins provide a class of heparins which are not only reliably absorbed in the subcutaneous fatty tissue, but also have a more predictable dose/effect relationship (Summary see [1, 2]). Furthermore, since the primary use of these heparins is associated far less commonly with the development of life-threatening HIT (heparin-induced thrombocytopenia) (3), their routine use is considered increasingly often, even for patients with heart disease. In this context, the unstable coronary syndrome (unstable angina pectoris and nontransmural myocardial infarction) is assuming a pioneering role in cardiology.

Schlüsselwörter

Akutes Koronarsyndrom - instabile Angina - niedermolekulare Heparine

Keywords

Acute coronary syndrome - unstable angina pectoris - LMWH

Full Text

References

Literatur
1 Gulba DC. Gerinnungshemmende Substanzen. Herz 1996; 21: 12-27.
2 Hirsh J, Warkentin TE, Raschke R, Cranger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Chest 1998; 114: S489-510.
3 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
4 Davies MJ, Thomas AC. Plaque fissuring – The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
5 Farb A, Burke AP, Tang AL, Liang Y, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-63.
6 Virmani R, Kolodigie FD, Burke AP, Farb A, Schwarz SM. Lessons from sudden death. A comprehensive morphological classification scheme for arteriosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
7 Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989; 9 suppl. I: 119-1989.
8 Fuster V, Stein B, Badimon L, Badimon JJ, Ambrose JA, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990; 82 suppl. II: 47-59.
9 Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation 1995; 92: 657-71.
10 Badimon JJ, Ip J, Badimon L, Fuster V. Thrombosis and accelerated atherosclerosis in coronary bypass surgery and restenosis after percutaneous transluminal coronary angioplasty: implications for therapy. Coronary Artery Dis 1990; I: 170-9.
11 Cairns JA, Gent M, Singer J, Finnie KJ, Frogatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealy BJ, Tanser PH. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369-75.
12 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various catagories of patients. Br Med J 1994; 308: 81-106.
13 Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative Study. N Engl J Med 1983; 309: 396-403.
14 Théroux P, Waters D, Qui S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045-8.
15 Théroux P, Ouimet H, McCans J, Latour J, Joly P, Lévy G, Pelletier E, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
16 The FRISC Study Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
17 Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie GG, van der Meer J, Olaisson E, Undeland S, Ludwig K. for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary disease. Circulation 1997; 96: 61-8.
18 The FRAX.I.S.Study Group. Comparison of two treatment durations (6days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstavble angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischemic Syndrome). Eur Heart J 1999; 20: 1553-62.
19 Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
20 Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJLM, Salein D, Bayes de Luna A, Fox K, Lablanche J-M, Radley D, Premmereur J, Braunwald E. for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Circulation 1999; 100: 1593-601.
21 Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmeruer J, Braunwald E. for the TIMI 11B (Thrombolysis in Myocardial Infarction) and Essence (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary events) Investigators : Assesment of the treatment effect of Enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE Meta-analysis. Circulation 1999; 100: 1602-8.
22 Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo W. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the task force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-32.
23 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochmann JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith III EE, Steward DE, Théroux P, Gibbons RJ, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russel RO, Smith Jr SC. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2000; 102: 1193-209.
24 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith III EE, Steward DE, Théroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith Jr SC. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
25 Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-7.
26 Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II) Investigators. Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-15.
27 Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R. Low molecular weight heparin (Reviparin) in percutaneous transluminal coronary angioplasty - results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996; 28: 1437-43.
28 Brack MJ, Ray S, Chauhan A, Fox J, Hubner P, Schofield P, Harley A. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) Trial. JACC 1995; 26: 947-54.
29 Lablanche JM, McFadden E, Meneveau N, Lusson JR, Bertrand B, Metzger JP, Legrand V, Grollier G, Macaya C, de Bruyne B. Effect of Nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty. The FACT-study. Circulation 1997; 96: 3396-402.
30 Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, Ohmen M. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin restenosis (ERA) trial. Circulation 1994; 90: 908-14.
31 Glick A, Karnowski R, Michowich Y, Koifman B, Roth A, Laniado S, Keren G. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-8.
32 Hauck S, Dietz R, Gulba D. Is low-molecular-weight heparin feasable for the postoperative anticoagulation after prosthetic valve replacement. Ann Hematol 1996; 73 suppl. I: S58.
33 Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997; 23: 167-72.
34 Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kübler W. Long term anticoagulation with low molecular weight heparin in outpatients with side effect on oral anticoagulations. Nouv Rev Fr Hematol 1989; 31: 363-69.